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Nateglinide, a novel D-phenylalanine derivative,
stimulates insulin release via closure of KATP chan-
nels in pancreatic //-cell, a primary mechanism of
action it shares with sulfonylureas (SUs) and
repaglinide. This study investigated (1) the influ-
ence of ambient glucose levels on the insulinotropic
effects of nateglinide, glyburide and repaglinide,
and (2) the influence of the antidiabetic agents on
glucose-stimulated insulin secretion (GSIS) in vitro
from isolated rat islets. The EC50 of nateglinide to
stimulate insulin secretion was 14M in the pres-
ence of 3mM glucose and was reduced by 6-fold in
8mM glucose and by 16-fold in 16mM glucose, indi-
cating a glucose-dependent insulinotropic effect.
The actions of glyburide and repaglinide failed to
demonstrate such a glucose concentration-depen-
dent sensitization. When tested at fixed and equipo-
tent concentrations (---2x EC50 in the presence of.
8mM glucose) nateglinide and repaglinide shifted
the EC50s for GSIS to the left by 1.7mM suggesting
an enhancement of islet glucose sensitivity, while
glimepiride and glyburide caused, respectively, no
change and a right shift of the EC50. These data
demonstrate that despite a common basic mecha-
nism of action, the insulinotropic effects of different
agents can be influenced differentially by ambient
glucose and can differentially influence the islet
responsiveness to glucose. Further, the present
findings suggest that nateglinide may exert a more
physiologic effect on insulin secretion than com-
parator agents and thereby have less propensity to
elicit hypoglycemia in vivo.
Keywards: Rat pancreatic islets; Nateglinide; Glucose stimu-
lated insulin ’secretion; Glucose sensitivity; Static incubation
INTRODUCTION
The homeostatic maintenance of blood glucose
concentration is an integrated process pre-
dominantly regulated by the anti-hyper-
glycemic hormone insulin. When blood glucose
rises, uptake of glucose into the/-cells leads to
an elevation of ATP/ADP ratio and a sequence
of ionic events. The resultant increase in intra-
cellular Ca2 +triggers exocytosis and insulin
release. [1] The generation of insulin occurs
through a precursor, proinsulin, whose biosyn-
thesis is stimulated by nutrient secretagogue
like glucose. [2] Aside from nutrient secreta-
gogues, there are a number of non-nutrient
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agents, which exert insulinotropic action via
mechanisms other than stimulating the biosyn-
thesis of insulin. As representatives of a class of
non-nutrient insulin secretagogues, sulfony-
lureas (SUs) like glyburide (GLY) and glimepiri-
de (GLI) act on pancreatic ]B-cells by blocking
KATP channels. [3-5] Agents that share the prima-
ry mechanism of action with SUs include
repaglinide (REP), a non-SUs benzoic acid
derivative,[6-8] and nateglinide (NAT), a novel
oral hypoglycemic agent recently marketed.[9,1]
The structures of these hypoglycemic agents are
shown in Figure 1.
In treating type 2 diabetes, SUs and REP can
cause long-lasting hypoglycemia under both
normoglycemic and hyperglycemic conditions
in animal models. [11,2] NAT, on the other
hand, demonstrates an enhanced activity un-
der hyperglycemic conditions due to glucose-
sensitive action. [9,3,141 In line with the in vivo
data, our earlier study characterizing the KATP
channel-blocking effect by hypoglycemic drugs
showed that NAT but not GLY and REP had an
increased potency at elevated glucose concen-
tration. [151 The aim of the present study was to
obtain further evidence for a glucose-sensitive
insulinotropic action by NAT. We investigated
the interaction between glucose and NAT with
regard to the stimulation of insulin release in
vitro from rat pancreatic islets by determining
the influence of glucose concentration on NAT-
induced insulin secretion as well as the influ-
ence of NAT on glucose-stimulated insulin
secretion (GSIS). Such an interaction was also
studied with the comparator insulinotropic
agents like glyburide (GLY) and repaglinide
(REP). Our results indicated that the islet secre-
tory response to glucose stimulation was sensi-
tized by NAT and REP, but not by the SUs,
GLY and GLI. In addition, stimulation
of insulin secretion in vitro by NAT was
glucose-dependent while the effects of







FIGURE 1 Chemical structure of hypoglycemic agents NAT, GLY, GLI, and REP.
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MATERIALS AND METHODS
Islet Isolation
Pancreas were dissected from normal fed male
Sprague Dawley rats (250-275g), which were
euthanized with Na pentobarbital i.p. at
120mg/kg. Islets of Langerhans were isolated
by librase digestion (0.5mg/ml, Boebringer
Mannheim, Germany) followed by a Ficoll gra-
dient centrifugation. [16]
Islet Static Incubation Assay
Freshly isolated islets were handpicked under a
stereomicroscope by gentle suction through a
large firepolished pipette (---400pm diameter) into
60 15mm Petri dishes (Corning) 25ml ofDMEM
(Dulbecco’s Modified Eagle Medium, Gibco BR)
supplemented with 5mM glucose (G5-DMEM)
and 1% BSA (BSA was present in all incubation
media throughout the experiments). Islets were
preincubated in a humidified atmosphere of 95%
02 and 5% CO2 at 37C for 1 hour. At the end of
incubation, G5-DMEM medium was discarded
and replaced with glucose free DMEM (G0-
DMEM). Islets were then picked (2 islets/tube; 4
tubes/condition) into borosilicate glass tubes
(12 75 mm) containing 500 pl chilled G0-DMEM.
After islets were settled, 5001 2x treatment of the
acute glucose/drug concentrations was added to
each tube (1 ml final volume).
In the first study, the concentration-de-
pendence of in vitro insulin secretion induced
by hypoglycemic agents during lh static incu-
bation in the presence of low (3mM, G3), mod-
erately elevated (8mM, G8) and severely
elevated (16mM, G16) glucose was investigat-
ed. Each drug at 6-7 concentrations (4
tubes/concentration) including drug free con-
trol in the presence of G3, G8 and G16 were
orderly set in a rack. Tubes were incubated at
37C with intermittent hand shaking for 1
hour. In the second study, insulin secretion
during one hour incubation at eight glucose
concentrations (0, 3, 5, 6.5, 8, 9.5, 11 and
16mM, 4 tubes/each glucose concentration)
was measured in the presence or absence of
one test drug (NAT, GLY, GLI or REP) at com-
parably effective concentrations approximately
2x respective EC50s at G8. At the end of lh sta-
tic incubation, islet media (500bl/tube) were
transferred to 96 deep-well plates and stored at
-20C for subsequent insulin analysis.
Insulin Scintillation Proximity
Assay (SPA)
The incubation media were diluted by factors
ranging from lx to 20x depending on the concen-
trations of glucose/drugs/inhibitors. The diluted
media were assayed for insulin content with
SPA. [17] The assay employed commercially avail-
able products including a guinea pig anti-rat
insulin specific antibody (Linco Research Inc) and
scintillation proximity Type I reagent coupled to
protein A (Amersham Life Science), and was per-
formed as a single step assay. All samples were
assayed in duplicate. The preparation of 96 well
sample plates was made by sequentially pipetting
standard/unknown samples, anti-insulin serum,
125I-insulin tracer, and SPA reagent, and the final
volume equaled 175b1/well. The plates were
incubated and vortexed on a titer plate shaker for
approximately 18-20 hours overnight at room
temperature before being placed into a Wallac
Microbeta 1450 Liquid Scintillation Counter to be
read under a normalization protocol. The output
was in counts per minute (CPM).
Data Analysis
The sample insulin concentration was calculat-
ed by utilizing a template set up in Excel
spreadsheet that possessed statistical analysis
functions. The calculated concentration was
eventually adjusted to reflect the degree of
dilution. The intra- and inter-assay coefficients
of variation were generally between 5% and
8%. EC50s were calculated from 5-points
dose-response curves fit with 4-parameter Hill
sigmoidal equation in Sigmaplot (version 4.01).
However, in cases where high concentrations
of glucose/drugs caused a decrease of insulin
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release, the values were excluded from the
curve fitting analysis. Statistical significance
was determined with t-test (single-tailed). P <
0.05 was considered significantly different.
RESULTS
GSIS in Nutrient-free and Nutrient-rich
Incubation Media
To validate the islet static incubation assay and
insulin SPA assay, we investigated GSIS in physi-
ologically relevant nutrient-rich medium DMEM
or in nutrient-free buffers such as Phosphate
Buffered Saline (PBS) and Krebs Ringer Bicarbon-
ate (KRB). While DMEM was rich in amino acids,
the salines had glucose as the sole exogenous
substrate. In all three types of media, insulin
secretion from freshly isolated islets during 1
hour static incubation was stimulated by glucose
in a concentration-dependent fashion, as shown
in Figure 2. The characteristics of GSIS, however,
differed considerably from medium to medium in
several aspects: (1) the basal level of insulin
release (at GO) was significantly lower in DMEM
and KRB than in PBS; (2) the stimulation factor
was 3.5-fold in PBS, 16.2-fold in KRB, and 26.7-
fold in DMEM as glucose concentration increased
from 0 to 16mM; (3) the EC50s (glucose concentra-
tion at which a half-maximal insulin release was
achieved) were 5.8 mM and 6.0mM, respectively,
in PBS and DMEM; (4) in KRB, there was no sig-
nificant increment in GSIS at glucose concentra-
tion up to 10mM. Our results reinforce the
importance of selection of incubation media and
the presence of exogenous nutrients (e.g., amino
acids) for islet function, as have been repeatedly
discussed by others.[18-2] Thus, DMEM seems to
be an optimal choice for the study of insulin
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FIGURE 2 GSIS in various incubation media: DMEM (tri-
angle), PBS (square), and KRB (circle). Data are the mean +__
SEM (n 4). In some cases the error bars are smaller than the
dimension of the symbols and are therefore not visible. Ordi-
nate shows the cumulative amount of insulin during 1 hour
incubation in U/islet and IU equals 40pg insulin; ab-
scissa indicates glucose concentration in mM. Curves were
fitted with 4-parameter sigmoidal Hill equation.
Influence of Glucose on Secretagogue-
Induced Insulin Secretion (Study 1)
The basal insulin secretion (in the absence of
drug) during lh incubation was, respectively,
20.3 +_ 2.4, 62.4 2.3, and 192.6 ___
13.5 U/islet at
G3, GS, and at G16 (n =96), demonstrating a
glucose-dependence of insulin secretion. The
ability of NAT, GLY and REP to stimulate insulin
secretion was evaluated when the glucose con-
centration was maintained at 3 (G3), 8 (GS), or 16
(G16) raM. Representative results with REP at six
concentrations are shown in Figure 3, in which
the amount of insulin secretion at each glucose
level in the absence (basal) and presence of REP
are displayed. The basal insulin secretion in the
absence of REP (shown with empty symbols)
increased as glucose concentration is elevated.
REP stimulated insulin secretion in a concentra-
tion-dependent manner at all glucose concentra-
tions tested.
Parallel studies were carried out with NAT
and GLY. The concentration-response curves for
all drugs tested at G3, G8 and G16 were pooled
and shown, respectively, in Figures 4A, B, and C.
Drug-induced insulin secretion was expressed
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FIGURE 3 REP-stimulated insulin release from isolated rat
islets during 1 hour static incubation at glucose concentra-
tions of 3mM (filled square), 8mM (filled circle), and 16mM
(filled triangle). The corresponding empty symbols on the
left side of the curves denote the respective basal insulin
level in the absence of REP. Points represent data pooled
from 4 independent experiments each with 4 tubes/condi-
tion (i.e., n 16/condition). Ordinate shows insulin secretion
(U/islet) during 1 hour incubation, and 1 IxU equals 40 pg
insulin; abscissa indicates REP concentration (M) in a loga-
rithm scale.
as percent increase from basal (i.e., stimulation
factor) and EC50 values were determined from
the least square fitting of data with Hill sig-
moidal equation and shown in Table I. The
EC50s with NAT was 14.2 xM at G3, decreased
by 6-fold to 2.3 txM at G8 (NS), and by 16-fold to
0.9xM at G16, suggesting sensitization of the
insulinotropic effect of NAT by glucose. The
potency of GLY remained statistically
unchanged from G3 (EC50 of 31.6nM) to G8
(EC50 of 41.2nM), but decreased at G16 by 20-
fold with an ECs0 of 0.6 }xM. The EC50 of REP
had a moderate decrease of 5-fold at G8 (NS)
compared to that at G3. There was, however, no
further sensitization of REP effect at more ele-
vated glucose (G16).
Effect of NAT, GLY, GLI and REP
on GSIS (Study 2)
Insulin secretion from rat isolated islets during
1hour of static incubation at glucose concen-
trations of 1, 3, 5, 6.5, 8, 9.5, 11, and 16 mM were
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FIGURE 4 Concentration-dependent induction of insulin
release from isolated rat islets during 1 hour static incuba-
tion by NAT (square), GLY (triangle) and REP (circle) in the
presence of 3 mM, (Fig. 4A), 8 mM (Fig. 4B), and 16 mM glu-
cose (Fig. 4C). Ordinate shows % increase in insulin release
from the basal. Points represent data pooled from 4-6 inde-
pendent experiments each with 4 tubes/condition (i.e., n
16-24/condition). Curves are 4-parameter Hill sigmoidal fit-
ting of the points.
NAT. This concentration of NAT was approx-
imately 2 x of the ECs0 of insulinotropic effect by
NAT at glucose concentration of 8mM (2.3
Figure 5A illustrates the data of glucose-
insulin response pooled from six independent
experiments (n =4 in each experiment). The
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TABLE EC50s of insulinotropic effect of antidiabetic
agents at three glucose levels
Glucose Nateglinide Glyburide Repaglinide
3mM 14.2 taM 31.6 nM 0.1 xM
8mM 2.3 pM 41.2 nM 24.7 nM
16mM 0.9 xM* 0.6 lxM* 78.5 nM
indicates significant difference compared to data in 3mM
glucose.
EC50s were direct readouts of the parameters in curve fitting
of the data in Figures 4A, B, and C with Hill 4-parameter sig-
moidal equation using statistics function in Sigmaplot. In
case where plateau has not been reached, the EC50s were the
values anticipated by the regression equation.
EC50 values (glucose concentrations for a half-
maximal GSIS) obtained directly from the
parameters of Hill sigmoidal equation were
9.7 + 0.5mM in the absence of NAT and 8.0 +__
0.5mM in the presence of NAT. The left shift of
EC50 in the presence of NAT may be partially
interpreted as an increase in islet sensitivity to
glucose. Moreover, the insulinotropic effect of
NAT was additive to that of glucose, since the
presence of NAT substantially increased the
maximal value of GSIS.
Parallel studies on GSIS was performed in the
absence and presence of hypoglycemic drugs
GLY (100nM), GLI (100nM) and REP (50nM).
The concentrations of the drugs were so chosen
that they were about equally effective in stimu-
lating insulin secretion (approximately 2x
respective EC50s at G8 obtained from study 1).
While GLI had not been tested in study 1, a
A. NAT B. GLY
200
10 20 10 20
4oo
[glucose] (mM) [glucose] (mM)
C. REP D. GLI
10 20 t0 20
[glucose] (mM) [glucose] (raM)
FIGURE 5 GSIS in the absence (circle) and presence (square) of 5 txM NAT (A), 100 nM GLY (B), 50 nM REP (C), and 100 nM
GLI (D). Points represent data pooled from 4-6 independent experiments each with 4 groups/condition (i.e., n 16-24/condi-
tion). In some cases the error bars are smaller than the dimension of the symbols and are therefore not visible. Curves were fit-
ted with 4-parameter sigmoidal Hill equation and EC50s were directly read from fitting parameters. Ordinate shows the
cumulative amount of released insulin during hour incubation in U/islet/lh (1 txU equals 40pg of insulin); abscissa indi-
cates glucose concentration in mM.
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TABLE II Glucose concentration for a half-maximal GSIS
(Mean SEM)
Control (no drug) 1 Drug
Hypoglycemic drugs (mM) (mM)
NAT 9.7 0.5 8.0 0.5
GLY 11.7 0.7 15.1 1.6"
GLI 9.3 __+ 0.1 8.4 2.0
REP 11.6 0.8 9.3 0.1"
Data are the average of 4-6 experiments, each with 4
groups/condition (i.e., n 16-24/condition).
concentration of 100 nM was used in this study,
provided it was of similar potency with GLY.
The concentration-response curves are shown,
respectively, in Figures 5B, C and D. The EC50s
of GSIS with and without secretagogues are tab-
ulated (Tab. II). The EC50 of REP was reduced
by 2.3mM, a magnitude slightly greater than
that with NAT, suggesting an increased sensi-
tivity of islets to glucose. However, the SUs,
GLY and GLI, caused, respectively, a pro-
nounced increase (by 3.4 mM) and no change in
EC50s. In fact, GSIS in the presence of GLY hard-
ly reached plateau at the highest glucose con-
centration tested (16mM). The actual ECs0
might therefore be even greater than the value
obtained from Hill sigmoidal fitting.
DISCUSSION
The islet incubation assay in conjunction with
insulin SPA assay adopted in this work allowed
in vitro study of cumulative insulin secretion
from pancreatic islets during static incubations.
The method was validated through investiga-
tion of GSIS in nutrient-free or nutrient-rich
incubation media. While in all media insulin
was released in a glucose concentration-depen-
dent manner, the composition of media pro-
foundly altered the basic sigmoidal relationship.
The lower insulin secretory capacity in nutrient-
free salines may be attributable to multiple
factors such as (1) impairment of glucose-sens-
ing resulting from a reduced islet content of
glucokinase; (2) decrease in rate of glycolysis
resulting from insufficient activation of phos-
phofructokinase in response to a rise in hexose
concentration; (3) reduction of insulin content in
the islet cells. [21] It is therefore conceivable that
nutrient-free salines are inappropriate for in vitro
insulin study.
The present study assessed the influence of
glucose on in vitro insulin secretion stimulated
by hypoglycemic drugs. Our data showed that
the augmentation by NAT of insulin release was
glucose-sensitive, as evidenced by a respective
6- and 16-fold increase in potency with an eleva-
tion of glucose from 3mM to 8 and 16mM.
These changes, albeit not drastic, indicated an
ability of NAT to "self-correct" for the mainte-
nance of glucose homeostasis. These data are in
qualitative agreement with findings from stud-
ies utilizing the buffer-perfused pancreas[22] as
well as from in vivo studies in rat or dog.[11,12]
The glucose sensitization of the NAT’s
insulinotropic action in vitro and in vivo and the
glucose desensitization of GLY’s action are also
consistent with the observations that NAT
allows whereas SUs prevent nutrient-stimulated
protein biosynthesis in f3 cells. [23,24]
The glucose-sensitive insulinotropic effect of
NAT predicts that it would be a more effective
drug in hyperglycemic patients than in normal
individuals, depending, of course on the
"health" of the pancreas or the residual /3-cell
mass. In addition, the reduced insulinogenic
potency of NAT at low glucose level may be
translated to an increased safety margin due to
reduced propensity of serious hypoglycemia.
Conversely, GLY showed a greater potency at
low glucose concentrations, which may con-
tribute to relatively high risk of hypoglycemia
known to be associated with GLY therapy. [25-27]
The insulinotropic effect of REP was more
potent by 5-fold in the presence of moderately
high glucose (8mM) than in the presence of low
glucose (3mM). The sensitivity to glucose,
however, diminished at high glucose level of
16mM.
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The result of enhanced effectiveness of NAT
to stimulate insulin secretion at elevated than
normal glucose level is consistent with the
results from the study on KATP channel,I15]
which revealed a similar tendency of glucose-
sensitivity, i.e., NAT blocks KATP channels more
potently in high glucose (G16) than in normal
glucose (G5). The ECs0s of NAT (14.2M) and
GLY (31.6nM) to stimulate insulin secretion at
G3 correlate well with the IC50s of NAT (7.4pM)
and GLY (16.6nM) to block KATp channel in
]B-cells in the presence of physiological glucose.
However, the EC50 of REP to stimulate insulin
secretion in the study (134nM) was significantly
higher than would be expected based on IC50
obtained from KATP channel data (5nM). The
reason(s) for such a discrepancy are yet to be
established.
We found that the insulinotropic drugs tested
differentially altered the in vitro GSIS. NAT and
REP appeared to sensitize the secretory response
of islets to glucose in two ways: (1) their effect
was additive to the effect of glucose, as evi-
denced by an increase in maximal insulin
release in the presence of drugs (Figs. 5A and
5C); (2) both drugs left-shifted the ECs0s for
GSIS, suggesting an increased islet sensitivity to
glucose. The interpretation for such an interac-
tion between drugs and glucose is lacking at
present. Some recent studies indicated that GSIS
cannot be attributed solely either to the closing
of KATP channels following an increase in intra-
cellular ATP/ADP, or the role of glucose as a
nutrient to cover the energy expenditure in the
islet cells [28]. On the other hand, the
insulinotropic action of NAT is likely to be
mediated by KATP channel-independent as well
as KATP channel-dependent pathways, while
that of REP appears to be solely due to its clos-
ing of KATP channels in /-cells. [7,29] Taken
together, the closure of KATP channels may not
be sufficient to account fully for all the effects of
hypoglycemic agents upon glucose sensitivity as
well as other biophysical and biochemical vari-
ables in the islet cells.
The reported results on the effect of SUs on
GSIS are rather controversial and lack consen-
sus. The data in this study with SUs showed
that the insulinotropic effect of GLY and GLI
was additive to glucose stimulated insulin
release (Figs. 5B and 5D), since the maximal
insulin release was markedly increased in the
presence of SUs. These agents, however, failed
to increase sensitivity of islets to glucose as indi-
cated by an increase (with GLY) or no change
(GLI) of their EC50s. The data are ir agreement
with the in vivo results of Groop et al. [31 and
Ligtenberg et al.,[311 but deviate from those of
Veneman et al.,[321 who reported that gliclazide,
another SU, caused an apparent enhancement of
]-cell glucose sensitivity.
The mechanism(s) by which the non-SU
insulinotropic drugs (NAT and REP) and the
SUs (GLY and GLI) exerted differential effect on
GSIS are yet to be established. It is speculated
that the non-SU drugs bind to the SU receptor at
a molecular site distinct from that for SUs and
hence interact with glucose in a distinct pattern.
In this context, the existence of a common SU
receptor with distinct sites for GLY and REP[81
and the presence of a specific binding site for
NAT in addition to a common SU receptor[33]
have been proposed to be responsible for the
common and differential insulin-stimulating
processes by these drugs. Alternatively, the sen-
sitizing or desensitizing efficacy of hypo-
glycemic agents on GSIS may be linked to
differences in their capacity to be inserted into
the phospholipid domain of the plasma mem-
brane. SUs, GLY and GLI, have been known to
be internalized into -cells to exert their
action[21,341 while NAT appears to act extracellu-
larly. [35] This distinction may lead to different
modification of responsiveness to Ca2+ of the
effector system for insulin release and in turn,
different glucose-sensitivity of islets.
In conclusion, nateglinide demonstrated a
glucose-dependent and glucose-sensitizing
insulinotropic action on isolated rat islets. These
properties further distinguish nateglinide from
other SU receptor ligands, raise the question of
whether KATp-channel closure is the sole mecha-
nism of action of this agent and predict a low
hypoglycemic potential during therapeutic use
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of nateglinide.
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